Search research articles
Contact Us
Filters
Showing results (51-60 of 108) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Runzhe Chen, Won-Chul Lee, Junya Fujimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2017
4-1BB Agonist Focuses CD8<sup>+</sup> Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer
Donastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, et al.
Cancer Innovation
|
July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes
Sahil Seth, Runzhe Chen, Yang Liu, et al.
Nature Communications
|
September 27, 2018
RNA editing derived epitopes function as cancer antigens to elicit immune responses
Minying Zhang, Jens Fritsche, Jason Roszik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 15, 2018
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
René J Tavera, Marie-Andrée Forget, Young Uk Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
Sharia Hernandez, Edwin Roger Parra, Naohiro Uraoka, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2022
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Pedro Rocha, Jiexin Zhang, Raquel Laza-Briviesca, et al.
Cancer Research Communications
|
November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer
Van K Morris, Michael J Overman, Michael Lam, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 108) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Runzhe Chen, Won-Chul Lee, Junya Fujimoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 27, 2017
4-1BB Agonist Focuses CD8<sup>+</sup> Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer
Donastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, et al.
Cancer Innovation
|
July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes
Sahil Seth, Runzhe Chen, Yang Liu, et al.
Nature Communications
|
September 27, 2018
RNA editing derived epitopes function as cancer antigens to elicit immune responses
Minying Zhang, Jens Fritsche, Jason Roszik, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 15, 2018
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
René J Tavera, Marie-Andrée Forget, Young Uk Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
Sharia Hernandez, Edwin Roger Parra, Naohiro Uraoka, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2022
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Pedro Rocha, Jiexin Zhang, Raquel Laza-Briviesca, et al.
Cancer Research Communications
|
November 16, 2022
Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer
Van K Morris, Michael J Overman, Michael Lam, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Page
of 11